{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"24"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"36"}],"units":"Participants"}],"description":"Grade 3 thrombocytopenia is defined as having 25,000-50,000 /uL platelets\n\nGrade 4 thrombocytopenia is defined as having \\< 25,000 /uL platelets","groups":[{"description":"30 mg three days a week (Mondays, Wednesdays and Fridays).\n\n1 cycle was 28 days\n\nDose modifications for attributable toxicities allowed for reduction to:\n\n* 25 mg, 20 mg three times a week every week\n* Or 20 mg three times a week every other week. No dose re-escalation was allowed.\n\n  * The protocol was amended on 6/15/2010 because of concerns of toxicity to allow a starting dose of 25 mg; 12/36 (33%) patients were enrolled on the 25 mg dose.\n\nLBH589","id":"OG000","title":"LBH589"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"Assessed after 2nd cycle, every subsequent cycle for 6 cycles and then every 3 months. Once off-treatment, adverse events will be assessed for 30 days. The median (range) number of completed cycles of therapy was 5 (0- 32). Therefore, up to ~33 months.","title":"Number of Participants With Grade 3 and 4 Treatment-Related Thrombocytopenia","type":"SECONDARY","unitOfMeasure":"participants"}